Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 7.

Journal Article

Brandes, V, Scheffler, M., Kambartel, K., Ortiz-Cuaran, S., Scheel, A., Michels, S., Nogova, L., Fischer, R., Abdulla, D., Merkelbach-Bruse, S., Buettner, R., Sos, M. L. and Wolf, J. (2016). Targeting HER2-and MET co-amplification in patients with EGFR mutation resistant to EGFR-TKI therapy. Oncol. Res. Treat., 39. S. 172 - 173. BASEL: KARGER. ISSN 2296-5262

Fischer, R. N., Abdulla, D., Michels, S., Nogova, L., Brandes, V, Scheffler, M., Schaeffer, S., Scheel, A., Thurat, M., Vehreschild, M., Thomas, R., von Bergwelt-Baildon, M., Buettner, R. and Wolf, J. (2016). Bioluma: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer - A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition. Oncol. Res. Treat., 39. S. 92 - 94. BASEL: KARGER. ISSN 2296-5262

Koleczko, S., Schapers, C., Scheffler, M., Ihle, M., Kostenko, A., Michels, S., Fischer, R., Nogova, L., Serke, M., Kaminsky, B., Benedikter, J., Bruemmendorf, T. H., Ficker, J. H., Lorenz, J., Schulte, C., Schulze-Olden, S., Brandes, V, Abdulla, D., Ueckeroth, F., Thurat, M., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2016). A comprehensive analysis of potentially targetable genetic aberrations and clinical findings in 821 patients with squamous-cell NSCLC - a comparison of NGM and TCGA LUSC data. Oncol. Res. Treat., 39. S. 32 - 33. BASEL: KARGER. ISSN 2296-5262

Kostenko, A., Michels, S., Kron, F., Brandes, V, Fischer, R., Nogova, L., Scheffler, M., Fassunke, J., Merkelbach-Bruse, S., Scheel, A., Ueckeroth, F., Sueptitz, J., Gerigk, M., Heydt, C., Glossmann, J. -P, Buettner, R. and Wolf, J. (2016). Improved overall survival following implementation of next generation sequencing in routine diagnostics of advanced lung cancer in Germany: results of the Network Genomic Medicine. Oncol. Res. Treat., 39. S. 305 - 307. BASEL: KARGER. ISSN 2296-5262

Michels, S., Brandes, V, Thurat, M., Nogova, L., Scheffler, M., Fischer, R., Merkelbach-Bruse, S., Hellmich, M., Buettner, R. and Wolf, J. (2016). EATON: An open-label, multicenter, phase I dose-escalation trial of EGF816 and trametinib in patients with non-small cell lung cancer and acquired EGFR p.T790M positive resistance to 1st or 2nd generation EGFR TKI therapy - a trial in preparation. Oncol. Res. Treat., 39. S. 172 - 173. BASEL: KARGER. ISSN 2296-5262

Michels, S., Fischer, R., Heydt, C., Ihle, M., Scheffler, M., Scheel, A., Ortiz-Cuaran, S., Nogova, L., Brandes, V, Sos, M., Buettner, R., Merkelbach-Bruse, S. and Wolf, J. (2016). Mechanisms of primary and acquired resistance to 3rd generation EGFR TKI treatment in EGFR mutated lung adenocarcinoma. Oncol. Res. Treat., 39. S. 252 - 254. BASEL: KARGER. ISSN 2296-5262

Michels, S., Thurat, M., Schmalz, P., Pereira, E., Scheffler, M., Fischer, R., Sebastian, M., Abreu, D. R., Carcereny, E., Corral, J. J., Felip, E., Grohe, C., Insa, A., Thomas, M., Reck, M., Rothschild, S., Brandes, V, Nogova, L., Merkelbach-Bruse, S., Massuti, B., Buettner, R., Rosell, R. and Wolf, J. (2016). EUCROSS: A European phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations - Preliminary results. Oncol. Res. Treat., 39. S. 209 - 211. BASEL: KARGER. ISSN 2296-5262

This list was generated on Mon Mar 1 02:54:08 2021 CET.